Markers of childhood lupus nephritis indicating disease activity

Pediatric Nephrology

Volumn 26, Issue 3, 2011, Pages 401-410

  Edelbauer, Monika ^a   Kshirsagar, Sudhir ^a   Riedl, Magdalena ^a   Haffner, Dieter ^b   Billing, Heiko ^c   Tönshoff, Burkhard ^c   Ross, Sophia ^d   Dötsch, Jörg ^e   Amon, Oliver ^f   Fehrenbach, Henry ^g   Steuber, Christian ^h   Beissert, Antje ⁱ   Hager, Josef ^a   Wechselberger, Gottfried ^a   Weber, Lutz T ^j   Zimmerhackl, Lothar Bernd ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^e UNIVERSITY OF COLOGNE   (Germany)

^f UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^g Klinikum Memmingen   (Germany)

^h Klinikum Links der Weser   (Germany)

ⁱ UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^j LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

more..

Author keywords

Anti C1q antibodies; B cell activating factor; C1q; Complement activation products; Lupus nephritis; RANTES; Soluble VCAM 1

Indexed keywords

B CELL ACTIVATING FACTOR; BIOLOGICAL MARKER; COMPLEMENT; COMPLEMENT COMPONENT BB; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C5A; RANTES; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ADOLESCENT; AGE DISTRIBUTION; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CHILD; CHILDHOOD DISEASE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; HUMAN; IMMUNE SYSTEM; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; RELIABILITY; SCHOOL CHILD;

EID: 79955020376     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-010-1720-x     Document Type: Article

References (59)

1. K Yanaba JD Bouaziz T Matsushita CM Magro EW St Clair TF Tedder 2008 B-lymphocyte contributions to human autoimmune disease Immunol Rev 223 284 299 18613843 10.1111/j.1600-065X.2008.00646.x 1:CAS:528:DC%2BD1cXptlGlsbY%3D (Pubitemid 351986191)
2. VT Chu P Enghard S Schurer G Steinhauser B Rudolph G Riemekasten C Berek 2009 Systemic activation of the immune system induces aberrant BAFF and APRIL expression in B cells in patients with systemic lupus erythematosus Arthritis Rheum 60 2083 2093 19565488 10.1002/art.24628 1:CAS:528:DC%2BD1MXptlKrsrc%3D
3. MP Cancro DP D'Cruz MA Khamashta 2009 The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus J Clin Invest 119 1066 1073 19411764 10.1172/JCI38010 1:CAS:528:DC%2BD1MXlsFyrsL4%3D
4. L Das HI Brunner 2009 Biomarkers for renal disease in childhood Curr Rheumatol Rep 11 218 225 19604467 10.1007/s11926-009-0030-4 1:CAS:528: DC%2BC3cXhtFeku7rK
5. Q Fu X Chen H Cui Y Guo J Chen N Shen C Bao 2008 Association of elevated transcript levels of interferon-inducible chemokines with disease activity and organ damage in systemic lupus erythematosus patients Arthritis Res Ther 10 R112 18793417 10.1186/ar2510
6. L Bao RJ Quigg 2007 Complement in lupus nephritis: the good, the bad, and the unknown Semin Nephrol 27 69 80 17336690 10.1016/j.semnephrol.2006.09.009 1:CAS:528:DC%2BD2sXkt1Squrc%3D
7. MA Seelen MR Daha 2006 The role of complement in autoimmune renal disease Autoimmunity 39 411 415 16923541 10.1080/08916930600739688 1:CAS:528: DC%2BD28XhtFamtLvF (Pubitemid 44269619)
8. MJ Walport 2001 Complement. First of two parts N Engl J Med 344 1058 1066 11287977 10.1056/NEJM200104053441406 1:CAS:528:DC%2BD3MXivFGnu7s%3D (Pubitemid 32267977)
9. PE Spronk H Bootsma MG Huitema PC Limburg CG Kallenberg 1994 Levels of soluble VCAM-1, soluble ICAM-1, and soluble E-selectin during disease exacerbations in patients with systemic lupus erythematosus (SLE); a long-term prospective study Clin Exp Immunol 97 439 444 7521807 10.1111/j.1365-2249.1994. tb06107.x 1:STN:280:DyaK2czmtl2jug%3D%3D (Pubitemid 24283887)
10. SM Wellicome P Kapahi JC Mason Y Lebranchu H Yarwood DO Haskard 1993 Detection of a circulating form of vascular cell adhesion molecule-1: raised levels in rheumatoid arthritis and systemic lupus erythematosus Clin Exp Immunol 92 412 418 7685670 10.1111/j.1365-2249.1993.tb03413.x 1:CAS:528: DyaK3sXmsVOktbk%3D (Pubitemid 23183748)
11. AP Manderson M Botto MJ Walport 2004 The role of complement in the development of systemic lupus erythematosus Annu Rev Immunol 22 431 456 15032584 10.1146/annurev.immunol.22.012703.104549 1:CAS:528:DC%2BD2cXktlOgsL4%3D (Pubitemid 38680429)
12. MC Pickering M Botto PR Taylor PJ Lachmann MJ Walport 2000 Systemic lupus erythematosus, complement deficiency, and apoptosis Adv Immunol 76 227 324 11079100 10.1016/S0065-2776(01)76021-X 1:CAS:528:DC%2BD3cXosFSju7k%3D
13. M Trendelenburg J Marfurt I Gerber A Tyndall JA Schifferli 1999 Lack of occurrence of severe lupus nephritis among anti-C1q autoantibody-negative patients Arthritis Rheum 42 187 188 9920031 10.1002/1529-0131(199901)42: 1<187::AID-ANR24>3.0.CO;2-U 1:STN:280:DyaK1M7hs1Omuw%3D%3D (Pubitemid 29042588)
14. I Kozyro L Korosteleva D Chernoshej D Danner A Sukalo M Trendelenburg 2008 Autoantibodies against complement C1q in acute post-streptococcal glomerulonephritis Clin Immunol 128 409 414 18544473 10.1016/j.clim.2008.04.005 1:CAS:528:DC%2BD1cXhtVShtr3L
15. M Trendelenburg M Lopez-Trascasa E Potlukova S Moll S Regenass V Fremeaux-Bacchi J Martinez-Ara E Jancova ML Picazo E Honsova V Tesar S Sadallah J Schifferli 2006 High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis Nephrol Dial Transplant 21 3115 3121 16877491 10.1093/ndt/gfl436 1:CAS:528:DC%2BD28XhtVygurbN (Pubitemid 44567082)
16. JT Merrill JP Buyon 2005 The role of biomarkers in the assessment of lupus Best Pract Res Clin Rheumatol 19 709 726 16150399 10.1016/j.berh.2005.05. 004 1:CAS:528:DC%2BD2MXpvV2lur0%3D (Pubitemid 41258579)
17. JB Lefkowith GS Gilkeson 1996 Nephritogenic autoantibodies in lupus: current concepts and continuing controversies Arthritis Rheum 39 894 903 8651982 10.1002/art.1780390605 1:STN:280:DyaK283jt1Ciug%3D%3D (Pubitemid 26182056)
18. GG Illei E Tackey L Lapteva PE Lipsky 2004 Biomarkers in systemic lupus erythematosus. I. General overview of biomarkers and their applicability Arthritis Rheum 50 1709 1720 15188346 10.1002/art.20344 1:CAS:528: DC%2BD2cXlsFaqt7g%3D (Pubitemid 38725082)
19. RM Valentijn H van Overhagen HM Hazevoet J Hermans A Cats MR Daha EL van 1985 The value of complement and immune complex determinations in monitoring disease activity in patients with systemic lupus erythematosus Arthritis Rheum 28 904 913 4026886 10.1002/art.1780280810 1:STN:280:DyaL2M3nvFKjug%3D%3D (Pubitemid 15021485)
20. LG Hunsicker S Ruddy CB Carpenter PH Schur JP Merrill HJ Muller-Eberhard KF Austen 1972 Metabolism of third complement component (C3) in nephritis. Involvement of the classic and alternate (properdin) pathways for complement activation N Engl J Med 287 835 840 4627271 10.1056/NEJM197210262871701 1:STN:280:DyaE3s%2Fgs1GgtA%3D%3D
21. PH Schur 1982 Complement and lupus erythematosus Arthritis Rheum 25 793 798 7049183 10.1002/art.1780250715 1:STN:280:DyaL383ls1Ohug%3D%3D (Pubitemid 12022150)
22. G Sturfelt AG Sjoholm 1984 Complement components, complement activation, and acute phase response in systemic lupus erythematosus Int Arch Allergy Appl Immunol 75 75 83 6086533 10.1159/000233593 1:STN:280:DyaL2c3mtlGjsg%3D%3D (Pubitemid 14094447)
23. S Manzi JE Rairie AB Carpenter RH Kelly SP Jagarlapudi SM Sereika TA Medsger Jr R Ramsey-Goldman 1996 Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity Arthritis Rheum 39 1178 1188 8670328 10.1002/art.1780390716 1:STN:280:DyaK283ms1arug%3D%3D (Pubitemid 26240232)
24. A Ceribelli L Andreoli I Cavazzana F Franceschini A Radice L Rimoldi RA Sinico M Carlsson J Wieslander A Tincani 2009 Complement cascade in systemic lupus erythematosus: analyses of the three activation pathways Ann NY Acad Sci 1173 427 434 19758182 10.1111/j.1749-6632.2009.04921.x 1:CAS:528: DC%2BD1MXhtlCntrjP
25. AA Jesus CA Silva M Carneiro-Sampaio M Sheinberg CL Mangueira SK Marie BL Liphaus 2009 Anti-C1q antibodies in juvenile-onset systemic lupus erythematosus Ann NY Acad Sci 1173 235 238 19758156 10.1111/j.1749-6632.2009.04675.x 1:CAS:528:DC%2BD1MXhtlCntr%2FP
26. YL Wu GC Higgins RM Rennebohm EK Chung Y Yang B Zhou HN Nagaraja DJ Birmingham BH Rovin LA Hebert CY Yu 2006 Three distinct profiles of serum complement C4 proteins in pediatric systemic lupus erythematosus (SLE) patients: tight associations of complement C4 and C3 protein levels in SLE but not in healthy subjects Adv Exp Med Biol 586 227 247 16893076 10.1007/0-387-34134-X-16 1:CAS:528:DC%2BD1MXhtFWitL8%3D
27. MC Hochberg 1997 Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus Arthritis Rheum 40 1725 9324032 10.1002/art.1780400928 1:STN:280:DyaK2svmsVaisw%3D%3D
28. MB Ferraz J Goldenberg MO Hilario WA Bastos SK Oliveira EC Azevedo D di Napoli 1994 Evaluation of the 1982 ARA lupus criteria data set in pediatric patients. Committees of Pediatric Rheumatology of the Brazilian Society of Pediatrics and the Brazilian Society of Rheumatology Clin Exp Rheumatol 12 83 87 7741825 1:STN:280:DyaK2c3hsFamtA%3D%3D
29. JJ Weening VD D'Agati MM Schwartz SV Seshan CE Alpers GB Appel JE Balow JA Bruijn T Cook F Ferrario AB Fogo EM Ginzler L Hebert G Hill P Hill JC Jennette NC Kong P Lesavre M Lockshin LM Looi H Makino LA Moura M Nagata 2004 The classification of glomerulonephritis in systemic lupus erythematosus revisited J Am Soc Nephrol 15 241 250 14747370 10.1097/01.ASN.0000108969.21691. 5D (Pubitemid 38140764)
30. C Bombardier DD Gladman MB Urowitz D Caron CH Chang 1992 Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE Arthritis Rheum 35 630 640 1599520 10.1002/art. 1780350606 1:STN:280:DyaK383oslWrtg%3D%3D
31. HI Brunner BM Feldman C Bombardier ED Silverman 1999 Sensitivity of the Systemic Lupus Erythematosus Disease Activity Index, British Isles Lupus Assessment Group Index, and Systemic Lupus Activity Measure in the evaluation of clinical change in childhood-onset systemic lupus erythematosus Arthritis Rheum 42 1354 1360 10403262 10.1002/1529-0131(199907)42:7<1354::AID-ANR8>3.0. CO;2-4 1:STN:280:DyaK1MzjtVSmtA%3D%3D (Pubitemid 30265592)
32. DD Gladman D Ibanez MB Urowitz 2002 Systemic lupus erythematosus disease activity index 2000 J Rheumatol 29 288 291 11838846 (Pubitemid 34118775)
33. DD Gladman MB Urowitz A Kagal D Hallett 2000 Accurately describing changes in disease activity in Systemic Lupus Erythematosus J Rheumatol 27 377 379 10685800 1:STN:280:DC%2BD3c7kvVagtA%3D%3D (Pubitemid 30095467)
34. P Rahman DD Gladman D Ibanez MB Urowitz 2001 Significance of isolated hematuria and isolated pyuria in systemic lupus erythematosus Lupus 10 418 423 11434577 10.1191/096120301678646164 1:STN:280:DC%2BD38%2FhslWgtA%3D%3D (Pubitemid 32578617)
35. EM Hay PA Bacon C Gordon DA Isenberg P Maddison ML Snaith DP Symmons N Viner A Zoma 1993 The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus Q J Med 86 447 458 8210301 1:STN:280:DyaK2c%2Fit1yrtQ%3D%3D (Pubitemid 23223653)
36. CH Hinze M Suzuki M Klein-Gitelman MH Passo J Olson NG Singer KA Haines K Onel K O'Neil ED Silverman L Tucker J Ying P Devarajan HI Brunner 2009 Neutrophil gelatinase-associated lipocalin is a predictor of the course of global and renal childhood-onset systemic lupus erythematosus disease activity Arthritis Rheum 60 2772 2781 19714584 10.1002/art.24751
37. T Rubinstein M Pitashny B Levine N Schwartz J Schwartzman E Weinstein JM Pego-Reigosa TY Lu D Isenberg A Rahman C Putterman 2010 Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis Rheumatology (Oxford) 49 960 971 10.1093/rheumatology/kep468 1:CAS:528:DC%2BC3cXkvFKktrw%3D
38. SD Marks V Shah C Pilkington K Tullus 2010 Urinary monocyte chemoattractant protein-1 correlates with disease activity in lupus nephritis Pediatr Nephrol 25 2283 2288 20683619 10.1007/s00467-010-1605-z
39. C Bigler M Schaller I Perahud M Osthoff M Trendelenburg 2009 Autoantibodies against complement C1q specifically target C1q bound on early apoptotic cells J Immunol 183 3512 3521 19648280 10.4049/jimmunol.0803573 1:CAS:528:DC%2BD1MXhtVWrs7nE
40. KA Davies AM Peters HL Beynon MJ Walport 1992 Immune complex processing in patients with systemic lupus erythematosus. In vivo imaging and clearance studies J Clin Invest 90 2075 2083 1430231 10.1172/JCI116090 1:STN:280:DyaK3s%2FlsFCmsg%3D%3D
41. L Truedsson AA Bengtsson G Sturfelt 2007 Complement deficiencies and systemic lupus erythematosus Autoimmunity 40 560 566 18075790 10.1080/08916930701510673 1:CAS:528:DC%2BD2sXhsVagtrjJ (Pubitemid 350302182)
42. G Castellano AM Woltman AJ Nauta A Roos LA Trouw MA Seelen FP Schena MR Daha C van Kooten 2004 Maturation of dendritic cells abrogates C1q production in vivo and in vitro Blood 103 3813 3820 14726389 10.1182/blood-2003-09-3046 1:CAS:528:DC%2BD2cXjvF2iu74%3D (Pubitemid 38596300)
43. M Kaul M Loos 2001 Expression of membrane C1q in human monocyte-derived macrophages is developmentally regulated and enhanced by interferon-gamma FEBS Lett 500 91 98 11434933 10.1016/S0014-5793(01)02592-3 1:CAS:528: DC%2BD3MXkvVelsro%3D (Pubitemid 32575325)
44. P Blanco AK Palucka M Gill V Pascual J Banchereau 2001 Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus Science 294 1540 1543 11711679 10.1126/science.1064890 1:CAS:528: DC%2BD3MXosFGnurk%3D (Pubitemid 33063928)
45. MC Dall'era PM Cardarelli BT Preston A Witte JC Davis Jr 2005 Type I interferon correlates with serological and clinical manifestations of SLE Ann Rheum Dis 64 1692 1697 15843451 10.1136/ard.2004.033753 (Pubitemid 41667141)
46. X Feng H Wu JM Grossman P Hanvivadhanakul JD FitzGerald GS Park X Dong W Chen MH Kim HH Weng DE Furst A Gorn M McMahon M Taylor E Brahn BH Hahn BP Tsao 2006 Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus Arthritis Rheum 54 2951 2962 16947629 10.1002/art.22044 1:CAS:528: DC%2BD28XhtFWksLnL (Pubitemid 44497776)
47. MK Elliott T Jarmi P Ruiz Y Xu VM Holers GS Gilkeson 2004 Effects of complement factor D deficiency on the renal disease of MRL/lpr mice Kidney Int 65 129 138 14675043 10.1111/j.1523-1755.2004.00371.x 1:CAS:528: DC%2BD2cXmt1Wjtw%3D%3D (Pubitemid 38037497)
48. MB Vieyra PS Heeger 2010 Novel aspects of complement in kidney injury Kidney Int 77 495 499 20016462 10.1038/ki.2009.491 1:CAS:528: DC%2BC3cXisVans7g%3D
49. M Chen MR Daha CG Kallenberg 2010 The complement system in systemic autoimmune disease J Autoimmun 34 J276 286 20005073 10.1016/j.jaut.2009.11.014 1:CAS:528:DC%2BC3cXjtVCksL0%3D
50. E Muso K Sekita T Doi T Kuwahara H Yoshida T Tamura C Kawai Y Hamashima 1984 Immunopathological correlation between mesangial C3d-deposition and C3d-fixing circulating immune complexes in lupus nephritis Clin Immunol Immunopathol 32 351 358 6380844 10.1016/0090-1229(84)90278-2 1:STN:280:DyaL2c3otlGmsg%3D%3D (Pubitemid 14029800)
51. SE Wenderfer B Ke TJ Hollmann RA Wetsel HY Lan MC Braun 2005 C5a receptor deficiency attenuates T cell function and renal disease in MRLlpr mice J Am Soc Nephrol 16 3572 3582 16207826 10.1681/ASN.2005040373 1:CAS:528: DC%2BD28XhvFWqtQ%3D%3D (Pubitemid 46211278)
52. M Wittmann J Zwirner VA Larsson K Kirchhoff G Begemann A Kapp O Gotze T Werfel 1999 C5a suppresses the production of IL-12 by IFN-gamma-primed and lipopolysaccharide-challenged human monocytes J Immunol 162 6763 6769 10352296 1:CAS:528:DyaK1MXjtlKitbo%3D (Pubitemid 29309403)
53. L Bao I Osawe T Puri JD Lambris M Haas RJ Quigg 2005 C5a promotes development of experimental lupus nephritis which can be blocked with a specific receptor antagonist Eur J Immunol 35 2496 2506 16052609 10.1002/eji.200526327 1:CAS:528:DC%2BD2MXps1Gmuro%3D (Pubitemid 41179771)
54. L Bao M Haas DM Kraus BK Hack JK Rakstang VM Holers RJ Quigg 2003 Administration of a soluble recombinant complement C3 inhibitor protects against renal disease in MRL/lpr mice J Am Soc Nephrol 14 670 679 12595503 10.1097/01.ASN.0000051597.27127.A1 1:CAS:528:DC%2BD3sXht1Kjt70%3D (Pubitemid 36246011)
55. S David L Biancone C Caserta B Bussolati V Cambi G Camussi 1997 Alternative pathway complement activation induces proinflammatory activity in human proximal tubular epithelial cells Nephrol Dial Transplant 12 51 56 9027773 10.1093/ndt/12.1.51 1:CAS:528:DyaK2sXhs1OjsLY%3D
56. GJ Byrne A Ghellal J Iddon AD Blann V Venizelos S Kumar A Howell NJ Bundred 2000 Serum soluble vascular cell adhesion molecule-1: role as a surrogate marker of angiogenesis J Natl Cancer Inst 92 1329 1336 10944555 10.1093/jnci/92.16.1329 1:CAS:528:DC%2BD3cXmtlektrs%3D (Pubitemid 30660593)
57. K Nakatani H Fujii H Hasegawa M Terada N Arita MR Ito M Ono S Takahashi K Saiga S Yoshimoto M Iwano H Shiiki Y Saito M Nose 2004 Endothelial adhesion molecules in glomerular lesions: association with their severity and diversity in lupus models Kidney Int 65 1290 1300 15086468 10.1111/j.1523-1755.2004.00537. x 1:CAS:528:DC%2BD2cXjtFyqurg%3D (Pubitemid 38406967)
58. D Seron JS Cameron DO Haskard 1991 Expression of VCAM-1 in the normal and diseased kidney Nephrol Dial Transplant 6 917 922 1724689 1:STN:280: DyaK387oslaksg%3D%3D
59. HI Brunner ED Silverman T To C Bombardier BM Feldman 2002 Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage Arthritis Rheum 46 436 444 11840446 10.1002/art.10072 (Pubitemid 34136581)